We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
Read MoreHide Full Article
Key Takeaways
{\"0\":\"TGTX posted Q2 EPS of $0.17, missing estimates. However, revenues rose 92% to $141.1 million.\",\"1\":\"Briumvi U.S. sales hit $138.8 million in Q2, up 91% year over year and 16% sequentially.\",\"2\":\"TGTX raised 2025 revenue guidance to $585 million on continued Briumvi momentum.\"}
TG Therapeutics (TGTX - Free Report) reported earnings of 17 cents per share for the second quarter of 2025, which substantially missed the Zacks Consensus Estimate of 32 cents. The company had reported earnings of 4 cents per share in the year-ago quarter.
Revenues in the second quarter totaled $141.1 million, up almost 92% year over year, driven by the strong demand for the company’s sole marketed drug, Briumvi (ublituximab-xiiy). The figure beat the Zacks Consensus Estimate of $136 million.
Briumvi, an anti-CD20 monoclonal antibody, was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. The drug is also approved in the European Union, the United Kingdom, Australia and Switzerland.
The top line comprised product sales from Briumvi and license, royalty and other revenues.
Shares of TG Therapeutics were down 18% on Aug. 4, probably due to the mixed earnings announcement.
The stock has declined 4.6% so far this year against the industry’s increase of 0.2%.
Image Source: Zacks Investment Research
TGTX's Q2 Earnings in Detail
Briumvi's net product sales were $138.8 million in the second quarter in the United States, reflecting an increase of 91% year over year. Sales of the drug increased 16% sequentially.
License, milestone, royalty and other revenues were $2.3 million in the reported quarter, compared with $0.9 million reported in the year-ago quarter.
TG Therapeutics has an agreement with Neuraxpharm Pharmaceuticals for the ex-U.S. commercialization of Briumvi, wherein the company is entitled to receive payments upon the achievement of certain commercial milestones and targets.
Research and development expenses (excluding non-cash compensation) increased around 83.3% year over year to $27.5 million due to higher manufacturing expenses related to the development of the subcutaneous formulation of Briumvi.
Selling, general and administrative expenses (excluding non-cash compensation) totaled $43.5 million, up almost 36.8% from the year-ago quarter’s level, due to higher commercialization costs for Briumvi as well as other personnel costs.
As of June 30, 2025, TG Therapeutics had cash, cash equivalents and investments worth $278.9 million compared with $276.2 million as of March 31, 2025.
2025 Guidance Raised
Owing to the continued growth in Briumvi revenues, TG Therapeutics raised its full-year revenue guidance for 2025.
The company now expects to record worldwide revenues of approximately $585 million in 2025 compared with the earlier expectation of $575 million.
For full-year 2025, net product sales of Briumvi are expected to be in the band of $570-$575 million in the United States, compared with the earlier projection of $560 million.
Operating expenses (excluding non-cash compensation and cost of goods sold) are expected to be around $300 million for full-year 2025 (unchanged from the previous guidance).
TGTX's Pipeline Updates
Several additional studies on Briumvi targeting other autoimmune diseases are currently ongoing.
The company plans to begin patient enrollment into the phase III pivotal program for subcutaneous Briumvi in RMS later in 2025.
Briumvi is also being studied for treating patients with myasthenia gravis, a rare and chronic autoimmune disorder that causes muscle weakness.
TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 52.7%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Arvinas’ 2025 loss per share have narrowed from $1.51 to $1.50. Loss per share estimates for 2026 have narrowed from $3.08 to $2.98 during the same period. ARVN stock has plunged 60.7% year to date.
Arvinas’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 10.3% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
Key Takeaways
TG Therapeutics (TGTX - Free Report) reported earnings of 17 cents per share for the second quarter of 2025, which substantially missed the Zacks Consensus Estimate of 32 cents. The company had reported earnings of 4 cents per share in the year-ago quarter.
Revenues in the second quarter totaled $141.1 million, up almost 92% year over year, driven by the strong demand for the company’s sole marketed drug, Briumvi (ublituximab-xiiy). The figure beat the Zacks Consensus Estimate of $136 million.
Briumvi, an anti-CD20 monoclonal antibody, was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. The drug is also approved in the European Union, the United Kingdom, Australia and Switzerland.
The top line comprised product sales from Briumvi and license, royalty and other revenues.
Shares of TG Therapeutics were down 18% on Aug. 4, probably due to the mixed earnings announcement.
The stock has declined 4.6% so far this year against the industry’s increase of 0.2%.
Image Source: Zacks Investment Research
TGTX's Q2 Earnings in Detail
Briumvi's net product sales were $138.8 million in the second quarter in the United States, reflecting an increase of 91% year over year. Sales of the drug increased 16% sequentially.
License, milestone, royalty and other revenues were $2.3 million in the reported quarter, compared with $0.9 million reported in the year-ago quarter.
TG Therapeutics has an agreement with Neuraxpharm Pharmaceuticals for the ex-U.S. commercialization of Briumvi, wherein the company is entitled to receive payments upon the achievement of certain commercial milestones and targets.
Research and development expenses (excluding non-cash compensation) increased around 83.3% year over year to $27.5 million due to higher manufacturing expenses related to the development of the subcutaneous formulation of Briumvi.
Selling, general and administrative expenses (excluding non-cash compensation) totaled $43.5 million, up almost 36.8% from the year-ago quarter’s level, due to higher commercialization costs for Briumvi as well as other personnel costs.
As of June 30, 2025, TG Therapeutics had cash, cash equivalents and investments worth $278.9 million compared with $276.2 million as of March 31, 2025.
2025 Guidance Raised
Owing to the continued growth in Briumvi revenues, TG Therapeutics raised its full-year revenue guidance for 2025.
The company now expects to record worldwide revenues of approximately $585 million in 2025 compared with the earlier expectation of $575 million.
For full-year 2025, net product sales of Briumvi are expected to be in the band of $570-$575 million in the United States, compared with the earlier projection of $560 million.
Operating expenses (excluding non-cash compensation and cost of goods sold) are expected to be around $300 million for full-year 2025 (unchanged from the previous guidance).
TGTX's Pipeline Updates
Several additional studies on Briumvi targeting other autoimmune diseases are currently ongoing.
The company plans to begin patient enrollment into the phase III pivotal program for subcutaneous Briumvi in RMS later in 2025.
Briumvi is also being studied for treating patients with myasthenia gravis, a rare and chronic autoimmune disorder that causes muscle weakness.
TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
TG Therapeutics, Inc. price-consensus-eps-surprise-chart | TG Therapeutics, Inc. Quote
TGTX's Zacks Rank & Stocks to Consider
TG Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) , Arvinas (ARVN - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 52.7%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Arvinas’ 2025 loss per share have narrowed from $1.51 to $1.50. Loss per share estimates for 2026 have narrowed from $3.08 to $2.98 during the same period. ARVN stock has plunged 60.7% year to date.
Arvinas’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 10.3% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.